A strategy for combating drug-resistant cancers

Many cancer therapies function by activating proteins like Caspase-3 (CASP3) that promote cell death. Several forms of cancer develop resistance to these drugs by down regulating CASP3 through an unknown mechanism. In the absence of CASP3, tumor cells produce another cell death promoting protein CASP7, but it is rendered inactive by the X-linked inhibitor of apoptosis protein (XIAP).

In this issue of the Journal of Clinical Investigation, Po-Huang Liang and colleagues at Academia Sinica identify a compound (I-Lys) that disrupts the interaction between CASP7 and XIAP. Release of CASP7 from this complex in drug activated cell death and reduced malignancies. Furthermore, no adverse side effects were observed in non- treated with the drug.

In the accompanying commentary, Gregory Gores from the Mayo Clinic explains that these results are promising for combatting drug resistant cancers, but more work needs to be done to establish if I-Lys will be safe and beneficial for human use.

More information: Targeting the XIAP/caspase-7 complex selectively kills caspase-3–deficient malignancies, J Clin Invest. 2013;123(9):3861–3875. DOI: 10.1172/JCI67951
Unshackling caspase-7 for cancer therapy, J Clin Invest. 2013;123(9):3706–3708. DOI: 10.1172/JCI71440

add to favorites email to friend print save as pdf

Related Stories

Targeting pancreatic cancer drug resistance

Jul 08, 2013

Pancreatic cancer is one of the most deadly and intractable forms of cancer, with a 5-year survival rate of only 6%. Novel therapies are urgently needed, as conventional and targeted approaches have not been successful and ...

Recommended for you

Video: Is that double mastectomy really necessary?

3 hours ago

When Angeline Vuong, 27,was diagnosed with cancer in one breast earlier this year, her first reaction was "A DOUBLE MASTECTOMY. NOW. " Turns out, she's far from alone: a recent JAMA study of 190,000 breast cancer cases in ...

User comments